IQVIA (United States)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. IQVIA (United Kingdom)英国5
2. United States Food and Drug Administration美国4
3. Amgen (United States)美国3
4. University of Utah美国2
5. GlaxoSmithKline (United States)美国2
6. GlaxoSmithKline (United Kingdom)英国2
7. Carelon Research (United States)美国2
8. Duke University美国2

按月发文

逐年被引

最新文献

1. 1
   The Guardian Research Network: A Real‐World Data Source for Pharmacoepidemiologic Research and Regulatory ApplicationsPharmacoepidemiology and Drug Safety20251
2. 2
   External Comparator Studies: Performance of Four Missing Data-Handling Approaches, Stratified by Four Different Marginal EstimatorsDrug Safety20252
3. 3
   Relationship Between Timing of PCSK9 Inhibitor Monoclonal Antibody Initiation and Clinical Outcomes in Patients with Prior Cardiovascular EventsTherapeutics and Clinical Risk Management20250
4. 4
   Safety Monitoring of Bivalent COVID ‐19 mRNA Vaccines Among Recipients 6 Months and Older in the United StatesPharmacoepidemiology and Drug Safety20257
5. 5
   Core Concepts in Pharmacoepidemiology: Principled Use of Artificial Intelligence and Machine Learning in Pharmacoepidemiology and Healthcare ResearchPharmacoepidemiology and Drug Safety20248
6. 6
   Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing TrendsDrug Safety202335
7. 7
   Considerations for defining medication exposure when analyzing real‐world dataPharmacoepidemiology and Drug Safety20233
8. 8
   Effectiveness and use of reverse transcriptase polymerase chain reaction point of care testing in a large‐scale COVID ‐19 surveillance systemPharmacoepidemiology and Drug Safety20227
9. 9
   Patient Global Impression of Benefit–Risk (PGI-BR): Incorporating Patients’ Views of Clinical Benefit–Risk into Assessment of New MedicinesDrug Safety20215
10. 10
    Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trialsPharmacoepidemiology and Drug Safety202074

高被引文献

1. 1
   Methods for external control groups for single arm trials or long‐term uncontrolled extensions to randomized clinical trialsPharmacoepidemiology and Drug Safety202074
2. 2
   Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reportingPharmacoepidemiology and Drug Safety201954
3. 3
   Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany – results of a database analysis from May 2010 to April 2012BMC Public Health201547
4. 4
   Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug ReactionsDrug Safety202037
5. 5
   Impact of European Union Label Changes for Fluoroquinolone-Containing Medicinal Products for Systemic and Inhalation Use: Post-Referral Prescribing TrendsDrug Safety202335
6. 6
   Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome associationPharmacoepidemiology and Drug Safety201629
7. 7
   The Role of Pharmacovigilance and ISoP During the Global COVID-19 PandemicDrug Safety202026
8. 8
   Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)Pharmacoepidemiology and Drug Safety201522
9. 9
   Evidence generation from healthcare databases: recommendations for managing changePharmacoepidemiology and Drug Safety201621
10. 10
    Comparative safety of atypical antipsychotics and the risk of pneumonia in the elderlyPharmacoepidemiology and Drug Safety201520

主要发表期刊

研究主题